Cargando…
The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis
BACKGROUND: The safety of antiplatelet therapy in haemodialysis (HD) patients remains controversial. we conducted the first meta-analysis to evaluate the bleeding risk with antiplatelet agents in these populations. METHODS: The relevant literature was searched using the following electronic database...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098092/ https://www.ncbi.nlm.nih.gov/pubmed/32216763 http://dx.doi.org/10.1186/s12882-020-01757-1 |
_version_ | 1783511119209431040 |
---|---|
author | Wang, Qi Xie, Xiaojie Xu, Gaosi |
author_facet | Wang, Qi Xie, Xiaojie Xu, Gaosi |
author_sort | Wang, Qi |
collection | PubMed |
description | BACKGROUND: The safety of antiplatelet therapy in haemodialysis (HD) patients remains controversial. we conducted the first meta-analysis to evaluate the bleeding risk with antiplatelet agents in these populations. METHODS: The relevant literature was searched using the following electronic databases without any language restrictions: the Cochrane Library, EMBASE, Global Health, MEDLINE, PubMed, and the Chinese Biomedical Database. RESULTS: Seven randomized controlled trials (RCTs) and 2 prospective cohort studies, consisting of 1131 patients, were identified for detailed evaluation. The meta-analysis suggested that the use of double antiplatelet agents increased the risk of bleeding in HD patients [odds ratio (OR) = 2.78; 95% confidence interval (CI) 1.63 to 4.76; I(2) = 0], and antiplatelet agents increased the risk of bleeding in 7 RCTs [odds ratio (RR) = 1.40, 95% CI 1.08 to 1.79; I(2) = 23%,]; however, the use of a single antiplatelet agent was not found to significantly increase the risk of bleeding (RR = 0.88; 95% CI 0.51 to 1.50; I(2) = 0). CONCLUSION: The results suggested that the use of double antiplatelet agents increased the risk of bleeding in HD patients. |
format | Online Article Text |
id | pubmed-7098092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70980922020-03-27 The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis Wang, Qi Xie, Xiaojie Xu, Gaosi BMC Nephrol Research Article BACKGROUND: The safety of antiplatelet therapy in haemodialysis (HD) patients remains controversial. we conducted the first meta-analysis to evaluate the bleeding risk with antiplatelet agents in these populations. METHODS: The relevant literature was searched using the following electronic databases without any language restrictions: the Cochrane Library, EMBASE, Global Health, MEDLINE, PubMed, and the Chinese Biomedical Database. RESULTS: Seven randomized controlled trials (RCTs) and 2 prospective cohort studies, consisting of 1131 patients, were identified for detailed evaluation. The meta-analysis suggested that the use of double antiplatelet agents increased the risk of bleeding in HD patients [odds ratio (OR) = 2.78; 95% confidence interval (CI) 1.63 to 4.76; I(2) = 0], and antiplatelet agents increased the risk of bleeding in 7 RCTs [odds ratio (RR) = 1.40, 95% CI 1.08 to 1.79; I(2) = 23%,]; however, the use of a single antiplatelet agent was not found to significantly increase the risk of bleeding (RR = 0.88; 95% CI 0.51 to 1.50; I(2) = 0). CONCLUSION: The results suggested that the use of double antiplatelet agents increased the risk of bleeding in HD patients. BioMed Central 2020-03-26 /pmc/articles/PMC7098092/ /pubmed/32216763 http://dx.doi.org/10.1186/s12882-020-01757-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Wang, Qi Xie, Xiaojie Xu, Gaosi The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis |
title | The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis |
title_full | The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis |
title_fullStr | The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis |
title_full_unstemmed | The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis |
title_short | The risk of bleeding for antiplatelet agents in Haemodialysis patients: a Meta-analysis |
title_sort | risk of bleeding for antiplatelet agents in haemodialysis patients: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098092/ https://www.ncbi.nlm.nih.gov/pubmed/32216763 http://dx.doi.org/10.1186/s12882-020-01757-1 |
work_keys_str_mv | AT wangqi theriskofbleedingforantiplateletagentsinhaemodialysispatientsametaanalysis AT xiexiaojie theriskofbleedingforantiplateletagentsinhaemodialysispatientsametaanalysis AT xugaosi theriskofbleedingforantiplateletagentsinhaemodialysispatientsametaanalysis AT wangqi riskofbleedingforantiplateletagentsinhaemodialysispatientsametaanalysis AT xiexiaojie riskofbleedingforantiplateletagentsinhaemodialysispatientsametaanalysis AT xugaosi riskofbleedingforantiplateletagentsinhaemodialysispatientsametaanalysis |